Cardiovascular Risk Evaluation through Heart Rate Variability (HRV) Analysis in Patients with Psoriasis before and after 12 Weeks of Etanercept Therapy: A Preliminary Prospective Study by Concetta Potenza et al.
181ACTA DERMATOVENEROLOGICA CROATICA
Acta Dermatovenerol Croat                          2016;24(3):181-186                     ORIGINAL SCIENTIFIC ARTICLE
Cardiovascular Risk Evaluation through Heart Rate 
Variability (HRV) Analysis in Patients with Psoriasis  
before and after 12 Weeks of Etanercept Therapy:  
A Preliminary Prospective Study
Concetta Potenza1#, Gianfranco Raimondi2#, Riccardo Pampena1, 
Nicoletta Bernardini1, Giorgio La Viola1, Ersilia Tolino1, Sara Zuber1, 
Beatrice Scordamaglia2, Nevena Skroza1
1Department of Medical and Surgical Sciences and Biotechnologies, Division of  
Dermatology “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, Italy;  
2Department of Medical and Surgical Sciences and Biotechnologies, Faculty of  
Pharmacy and Medicine, Sapienza University of Rome, Italy
# These authors contributed equally to this work.
Corresponding Author: 
Riccardo Pampena, MD
Dermatology Unit “Daniele Innocenzi”,
“Sapienza” University of Rome
A. Fiorini Hospital, via Firenze, snc
04019, Terracina (LT) 
Italy 
riccardopampena@gmail.com
Received: July 7, 2015
Accepted: May 30, 2016
ABSTRACT The association between psoriasis and cardiovascular diseases has 
been indicated by epidemiological studies. The sub-inflammatory systemic 
state that characterizes both psoriasis and atherosclerosis has been proposed 
as the link between these conditions; it cannot, however, explain the increased 
incidence of sudden cardiac death reported in young patients with severe 
psoriasis without common cardiovascular risk factors. In a previous study, we 
reported higher levels of autonomic dysregulation in patients with psoriasis, 
concluding that the prevalence of the sympathetic arm over the parasympa-
thetic could increase cardiovascular risk. Objective of this study was to assess 
the influence of etanercept on autonomic cardiovascular regulation in young 
patients with moderate-to-severe psoriasis without cardiovascular risk factors. 
Five-minute ECG recordings were collected at rest before and after 12 weeks of 
therapy with etanercept in 19 young patients with psoriasis without cardiovas-
cular risk factors. The Cardiolab CE pocket PC ECG system was used for linear 
methods of heart rate variability (HRV) analysis. No significant change in HRV 
analysis parameters was apparent after 12 weeks of etanercept therapy. Our 
data suggest that treatment with etanercept in patients with moderate-to-se-
vere psoriasis does not affect cardiovascular autonomic regulation and cardio-
vascular risk.
KEY WORDS: etanercept; cardiovascular risk; heart rate variability analysis; 
psoriasis
INTRODUCTION
Psoriasis is a common chronic inflammatory skin 
disease affecting 3% of the Caucasian population (1) 
and is associated with systemic manifestations such 
as arthritis, hypertension, dyslipidemia, and metabolic 
syndrome (2). In particular, of emerging significance 
is the relationship between cardiovascular diseases 
(CVDs) and psoriasis (3), as increased mortality, mainly 
related to myocardial infarction and ventricular arrhyth-
mias, has been reported in patients with severe psoria-
sis (Psoriasis Area Severity Index (PASI) score ≥10) (4,5). 
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Recently, a meta-analysis indicated a higher risk of 
cardiovascular (CV) events in patients with psoriasis 
when compared to non-psoriatic controls (odds ratio 
(OR) 1.28, 95% confidence interval (CI) 1.18-1.38) (6); 
nevertheless it is still debated if the increase in CV 
morbidity and mortality can be attributable solely to 
psoriasis (7). Common pathogenic mechanisms have 
been proposed for psoriasis and CVDs. Griffiths et al. 
suggested that the increased inflammatory burden 
of the patient with psoriasis can cause a state of in-
sulin resistance, resulting in endothelial cell dysfunc-
tion and atherosclerosis; when coronary, carotid, or 
cerebral arteries are involved, this cascade will result 
in myocardial infarction or stroke (8). As supporting 
proof, the increase of intima-media thickness and 
coronary calcifications has been documented in pa-
tients with psoriasis (9). These are perhaps only a part 
of the pathogenic mechanisms shared by CVDs and 
psoriasis.
Heart rate variability (HRV) analysis is a non-in-
vasive and easy-to-perform method to evaluate the 
autonomic control of the sinus node (10). A higher 
prevalence of the sympathetic arm, assessed by HRV, 
has been associated with an increased CV risk in the 
general population (11,12). However, no published 
studies have used HRV analysis to assess the effects 
of biologic drugs on the CV system in patients with 
psoriasis. The association between these drugs and 
CVDs (myocardial infarction and/or heart failure) is 
still controversial (13,14). Nevertheless, the label of 
etanercept (a soluble tumor necrosis factor (TNF)-al-
pha receptor inhibitor) reports the following disease-
related warning: “Use with caution in patients with 
heart failure or decreased left ventricular function”. 
Given the evidence to date, Sinagra et al. suggest that 
treatment strategies other than TNF-alpha inhibitors 
should be employed in patients with symptomatic 
heart failure. A drug-induced cause should be sus-
pected in patients who develop heart failure while 
receiving a TNF-alpha inhibitor, and use of the medi-
cation should be suspended (15).
An open-label study was performed to assess 
whether etanercept treatment influences the auto-
nomic CV regulation (evaluated with HRV analysis) 
and CV risk in a population of young patients with 




We enrolled consecutive patients with psoriasis 
who attended our outpatient clinic from October 
2013 to February 2014. The inclusion criteria were: 
age between 18 and 35 years, diagnosis of moder-
ate-to-severe cutaneous psoriasis (PASI >10), and ab-
sence of psoriatic arthritis or other forms of psoriasis; 
no assumption of both long-term (psycho-drugs) and 
short-term modifiers of the autonomic function; no 
previous treatment with biologic agents for psoriasis, 
and a period of at least 12 weeks of wash-out from 
traditional drugs for psoriasis (cyclosporine, acitretin, 
methotrexate); absence of the common CV risk fac-
tors, including smoking habit, metabolic syndrome, 
hypertension, family history of CVDs, and being over-
weight, defined as body mass index (BMI) >25.
Metabolic syndrome was defined as the presence 
of at least 3 of 5 criteria according to the 2009 Joint 
Scientific Statement: waist circumference ≥102 cm 
(88 for women), triglycerides ≥150 mg/dL, blood pres-
sure (BP) ≥130/85 mmHg, high-density lipoprotein 
(HDL) cholesterol <40 mg/dL (50 mg/dL for women) 
and fasting plasma glucose ≥100 mg/dL (16).
Finally, any intoxicating agent (caffeine, theine) 
was forbidden within the three hours preceding the 
electrocardiogram (ECG) recording.
Each enrolled patient gave written informed con-
sent, and the study was conducted in accordance 
with the Declaration of Helsinki (17). 
Procedure
First, an accurate clinical (CV and dermatological) 
history was collected. Information about gender, age, 
waist circumference, HDL cholesterol, triglycerides, 
and fasting blood glucose was recorded and BMI and 
PASI were calculated.
Heart rate, BP, and a 5-minute digital ECG in rest 
conditions (supine position for 3 minutes before re-
cording) were then obtained from all the subjects 
included in the study at baseline (t0) and 12 weeks 
after first etanercept administration (t1). Linear meth-
ods, consisting of a time-domain analysis (traditional 
statistical analysis) and a frequency-domain analysis 
(spectral analysis), were used to analyze HRV. The Car-
diolab CE pocket PC ECG system (XAI-Medica, Khar-
kov, Ukraine) was used for ECG recording and data 
analysis.
Time-domain analysis included SDNN (Standard 
Deviation of all normal-to-normal (NN) intervals) and 
RMSSD (Root Mean Square Successive Difference be-
tween adjacent NNs). 
Frequency-domain analysis of HRV provides in-
formation on the frequency of periodic oscillations of 
the heart rate signal. Two principal bands can be iden-
tified: the low frequency band (LF) and the high fre-
quency band (HF). The HF component is considered 
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Patients (N=19)
Men, n (%) 11 (57.9)









HR (b/min) t0 66.1±12.2




Data are expressed as mean ± SD. 
FPG, fasting plasma glucose; WC, waist circumference; TG, 
triglycerides; HDL-c, high density lipoprotein-cholesterol; 
SAP, systolic arterial pressure; DAP, diastolic arterial 
pressure; HR, heart rate; BMI, body mass index; PASI, 
Psoriasis Area Severity Index.
*P=0.135 vs. t0.
†P<0.001 vs. t0.
Table 1. Registry data
to be a reliable index of vagal modulation, whereas 
both the sympathetic and the parasympathetic ner-
vous systems appear to be involved in modulating 
the LF component. The LF/HF ratio represents an in-
dex of sympatho-vagal balance (18).
Etanercept administration
Each patient enrolled in the study auto-admin-
istered etanercept according to the classical dos-
ing schedule of 50 mg × 2 per week for the first 12 
weeks (induction period) and subsequently 50 mg 
per week.
Statistical analysis
Data are expressed as mean ± standard deviation. 
Paired T-test for quantitative variables was used to 
compare baseline and week 12 data. Statistical analy-
sis was performed with SigmaStat 3.5 software for 
Windows. Statistical significance was fixed at P<0.05.
RESULTS
Nineteen consecutive psoriatic patients were en-
rolled in the study (11 male patients and 8 women, 
median age 28.5±4.9). Each of the enrolled patients 
completed the treatment. No side effects were re-
corded in the observation period. 
Table 1 summarizes the clinical findings in the 
whole group of patients at baseline and after 12 
weeks of treatment. Data showed a non-significant 
reduction of the mean heart rate at t1 compared to 
baseline (66.1±12.2 at t0 vs. 67.9±10.9 at t1; P=0.135). 
In contrast, a statistically significant improvement 
in PASI score was reported after 12 weeks (P<0.001; 
mean PASI at baseline: 12.6±3.1; mean PASI at week 
12: 5.7±0.9). 
Neither time-domain nor frequency-domain anal-
ysis showed a significant difference between t0 and 
t1 (Table 2). There was a non-significant decrease in 
both SDNN and RMSSD parameters with time-domain 
analysis, whereas frequency-domain analysis showed 
a non-significant decrease in total power and HF%, 
and a non-significant increase in LF% and LF/HF ratio. 
DISCUSSION
Psoriasis is now considered a systemic inflamma-
tory disorder, rather than a disease affecting only the 
skin or joints (19). An increased CV risk in patients with 
Table 2. Linear analysis: Time-domain analysis (traditional statistical analysis) and frequency-domain analy-
sis (spectral analysis)
T0 T1 p Value
Time Domain
SDNN (ms) 48.7±21.7 45.8±22.9 0.613
RMSSD (ms) 41.6±22.7 34.5±22.6 0.267
Frequency Domain
TOTAL ms2 2700.5±2429.0 2493.4±2455.1 0.757
LF% 53.6±17.2 60.5±13.9 0.121
HF% 46.4±17.2 39.5±13.9 0.121
LF/HF 1.5±1.1 1.9±1.3 0.142
Data are expresed as mean ± SD. 
SDNN, standard deviation of all normal-to-normal (NN) intervals; RMSSD, root mean square successive difference between 
adjacent NNs; LF, low frequencies; HF, high frequencies.
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psoriasis has been reported (20,21); however, no ran-
domized trials have been conducted to demonstrate 
the causal nature of this association. Several hypoth-
esis have been proposed to explain the link between 
psoriasis and CVDs  that have so far all focused on the 
common inflammatory subset of these disorders.
There is growing evidence that different subsets 
of T-helper (Th) cells are implicated in the pathogen-
esis of psoriasis; in particular Th-1, Th-17, and Th-22 
have been reported (22). Cardiovascular diseases 
are mainly related to atherosclerosis. Innate as well 
as adaptive immune responses have been identi-
fied during the course of atherosclerosis, also involv-
ing the Th-1 and Th-17 pathways (23). Inflammatory 
markers, such as white blood cell count, fibrinogen, 
ferritin, high-sensitivity C-reactive protein (hs-CRP), 
erythrocyte sedimentation rate (ESR), haptoglobin, 
ceruloplasmin, and α1-antitrypsin have been demon-
strated to be related to both psoriasis severity and CV 
risk (19). The reduction of these parameters (in par-
ticular hs-CRP, fibrinogen and ESR) has been shown 
to occur during therapy with etanercept, an anti-TNF-
alpha agent (24). 
In 2010, the European League against Rheuma-
tism (EULAR) recommended annual CV risk assess-
ment, as well as aggressive suppression of inflamma-
tory processes, in order to lower the risk for CV events 
in patients with arthritis, including psoriatic arthritis 
(25). Even if the evidence appears to definitively in-
dicate inflammation as the bridge between psoriasis 
and CVDs pathogenesis, it is not yet completely clear 
how inflammation can actually act. No studies in the 
literature have considered the role of the autonomic 
cardiac regulation. The heart is innervated by the sym-
pathetic and the parasympathetic nervous system. 
Parasympathetic fibers are carried in the vagus nerve 
and their discharge results in a decreased heart rate 
and, to a lesser extent, reduced contractility. The sym-
pathetic nervous system acts on the heart via direct 
neuronal control and also via the release of adrena-
line and noradrenaline, mediated by beta receptors. 
This results in an increased heart rate and increased 
myocardial contractility. Information on blood pres-
sure is fed to the brain from baroreceptors in the ven-
tricles, aortic arch, and carotid bodies (26).
In a previous study, we evaluated the effect of 
psoriasis on the autonomic nervous system using 
HRV analysis (27). We concluded that moderate pso-
riasis, in young naïve patients without CV comorbidi-
ties, might represent a possible independent CV risk 
factor, because a balanced reduction of the para-
sympathetic heart modulation associated with an 
increased sympathetic modulation of the sinus node 
was detected when comparing the study population 
with a homogenous control group. HRV analysis was 
performed with both the classical linear methods 
and with non-linear methods such as Poincaré plot, 
Detrended Fluctuation Analysis, and entropy analysis 
(28).
In the present study, we first used HRV analy-
sis to assess the effects of biologic drugs on the CV 
regulation. In particular, we showed that etanercept 
treatment does not modify the autonomic CV regula-
tion, and consequently the CV risk, in a population of 
young patients with moderate-to-severe psoriasis in 
absence of metabolic syndrome and other CV comor-
bidities. Both time-domain and frequency-domain 
linear HRV analysis failed to demonstrate a statisti-
cally significant difference between t0 and t1, even if 
both reported an unbalance toward the sympathetic 
arm. In particular, linear time-domain analysis (tradi-
tional statistical analysis) showed a reduction of the 
RMSSD values, considered as an index of parasympa-
thetic modulation, even if the effect did not reach sta-
tistical significance. Linear frequency-domain analysis 
(spectral analysis) showed a non-significant increase 
in oscillatory components attributable to sympathet-
ic activity (LF%) and a simultaneous decrease of the 
oscillatory components attributable to parasympa-
thetic modulation (HF%). Consequently, an increase 
in the LF/HF ratio was observed, which is considered 
an index of sympatho-vagal balance.
The principal limitation of our study is the low 
number of subjects enrolled, which was mainly relat-
ed to the strict inclusion criteria. As a pilot study, the 
evaluation of HRV during treatment was performed 
after 12 weeks of therapy; new data will come from 
further studies.
CONCLUSION
Our data suggest that etanercept therapy in pa-
tients with moderate-to-severe psoriasis does not 
modify CV regulation. Thus etanercept does not seem 
to influence the CV risk associated with psoriasis. This 
preliminary data needs to be validated by further 
studies. Finally, emerging evidence from the medical 
literature indicates that psoriasis and CVDs seem to 
be closely related, so we believe that CV screening 
should be mandatory in patients with psoriasis, espe-
cially when CV risk factors are present.
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